Drug Combination Details
| General Information of the Combination (ID: C85683) | |||||
|---|---|---|---|---|---|
| Name | Luteolin NP Info | + | Celecoxib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The combination of celecoxib and luteolin provided superior inhibition of breast cancer cell growth than either celecoxib or luteolin treatment alone. Decreased levels of Akt phosphorylation (pAkt) were noted after celecoxib and luteolin combination treatment. | |||||
| Experiment 2 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | BAD | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | BAK | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | BAX | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | ||
| MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | |||
| SK-BR-3 | CVCL_0033 | Breast adenocarcinoma | Homo sapiens | |||
| In-vivo Model | MDA-MB-231 cells (2*107) were inoculated subcutaneously into the right flanks of female BALB/c nude mice (6-7 weeks old). | |||||
| Experimental
Result(s) |
Synergistic effect between celecoxib and luteolin is dependent on estrogen receptor in human breast cancer cells. | |||||
